Two AIDS activist groups filed a complaint in South Africa against Merck, claiming the company does not grant enough licenses to generic companies to sell its AIDS drug Stocrin. Merck’s actions have prevented access to cheaper, generic versions of Stocrin (efavirenz), according to a complaint filed by the AIDS Law Project and the Treatment Action Campaign in the Competition Commission of South Africa. The company has violated South Africa’s Competition Act, the groups say…The complaint requests a compulsory license…